blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2118103

EP2118103 - AZAINDOLE DERIVATIVES AS CFTR MODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.02.2015
Database last updated on 24.08.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): MT		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210 / US
[2014/35]
Former [2014/09]For all designated states
Vertex Pharmaceuticals Inc.
50 Northern Avenue
Boston, MA 02210 / US
Former [2009/47]For all designated states
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139 / US
Inventor(s)01 / HADIDA RUAH, Sara
2356 Torrey Pines 16
La Jolla, CA 92037 / US
02 / ZHOU, Jinglan
4466 Shorepointe Way
San Diego, CA 92130 / US
03 / MILLER, Mark
5075 La Jolla Blvd., 9
San Diego, CA 92109 / US
04 / BEAR, Brian
5108 Spencer Court
Oceanside, CA 92057 / US
 [2009/47]
Representative(s)Oates, Edward Christopher, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2014/45]
Former [2014/44]Goodfellow, Hugh Robin, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Former [2014/17]Cohausz & Florack
Patent- und Rechtsanwälte
Partnerschaftsgesellschaft
Bleichstraße 14
40211 Düsseldorf / DE
Former [2009/47]Cohausz & Florack
Patent- und Rechtsanwälte Bleichstraße 14
40211 Düsseldorf / DE
Application number, filing date07873586.702.11.2007
[2009/47]
WO2007US83464
Priority number, dateUS20060856584P03.11.2006         Original published format: US 856584 P
[2009/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008127399
Date:23.10.2008
Language:EN
[2008/43]
Type: A2 Application without search report 
No.:EP2118103
Date:18.11.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 23.10.2008 takes the place of the publication of the European patent application.
[2009/47]
Type: B1 Patent specification 
No.:EP2118103
Date:23.04.2014
Language:EN
[2014/17]
Search report(s)International search report - published on:EP31.12.2008
ClassificationIPC:C07D471/04, A61K31/437, A61P3/00, A61P25/00
[2009/47]
CPC:
C07D471/04 (EP,KR); A61K31/437 (KR); A61P11/00 (EP);
A61P13/02 (EP); A61P13/12 (EP); A61P19/00 (EP);
A61P21/00 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P3/00 (EP); A61P3/06 (EP);
A61P3/08 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P5/10 (EP); A61P5/14 (EP); A61P5/16 (EP);
A61P5/18 (EP); A61P7/00 (EP); A61P7/04 (EP);
A61P7/10 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/47]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:AZAINDOLDERIVATE ALS CFTR-MODULATOREN[2009/47]
English:AZAINDOLE DERIVATIVES AS CFTR MODULATORS[2009/47]
French:DÉRIVÉS D'AZAINDOLE COMME MODULATEURS DE CFTR[2009/47]
Entry into regional phase30.04.2009National basic fee paid 
30.04.2009Designation fee(s) paid 
30.04.2009Examination fee paid 
Examination procedure30.04.2009Examination requested  [2009/47]
09.10.2009Amendment by applicant (claims and/or description)
18.12.2009Despatch of a communication from the examining division (Time limit: M06)
09.06.2010Reply to a communication from the examining division
25.02.2011Despatch of a communication from the examining division (Time limit: M06)
18.08.2011Reply to a communication from the examining division
03.08.2012Despatch of a communication from the examining division (Time limit: M04)
11.12.2012Reply to a communication from the examining division
07.11.2013Communication of intention to grant the patent
14.03.2014Fee for grant paid
14.03.2014Fee for publishing/printing paid
Divisional application(s)EP14164892.3  / EP2826778
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.12.2009
Opposition(s)26.01.2015No opposition filed within time limit [2015/14]
Fees paidRenewal fee
25.11.2009Renewal fee patent year 03
24.11.2010Renewal fee patent year 04
23.11.2011Renewal fee patent year 05
26.11.2012Renewal fee patent year 06
27.11.2013Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
MC23.04.2014
MT23.04.2014
PL23.04.2014
RO23.04.2014
SI23.04.2014
SK23.04.2014
TR23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
LU02.11.2014
[2016/33]
Former [2016/32]CY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
MC23.04.2014
PL23.04.2014
RO23.04.2014
SI23.04.2014
SK23.04.2014
TR23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
LU02.11.2014
Former [2015/36]CY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
MC23.04.2014
PL23.04.2014
RO23.04.2014
SI23.04.2014
SK23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
LU02.11.2014
Former [2015/32]CY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
MC23.04.2014
PL23.04.2014
RO23.04.2014
SK23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
LU02.11.2014
Former [2015/30]CY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
PL23.04.2014
RO23.04.2014
SK23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
LU02.11.2014
Former [2015/11]CY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
PL23.04.2014
RO23.04.2014
SK23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
Former [2015/10]CY23.04.2014
CZ23.04.2014
DK23.04.2014
EE23.04.2014
LT23.04.2014
LV23.04.2014
PL23.04.2014
SK23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
Former [2015/08]CY23.04.2014
DK23.04.2014
LT23.04.2014
LV23.04.2014
PL23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
Former [2015/02]CY23.04.2014
LT23.04.2014
LV23.04.2014
PL23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
PT25.08.2014
Former [2014/50]CY23.04.2014
LT23.04.2014
LV23.04.2014
PL23.04.2014
BG23.07.2014
GR24.07.2014
IS23.08.2014
Former [2014/49]CY23.04.2014
LT23.04.2014
BG23.07.2014
IS23.08.2014
Former [2014/48]CY23.04.2014
LT23.04.2014
BG23.07.2014
Former [2014/47]CY23.04.2014
Cited inInternational search[X]WO2005063746  (PHARMACIA ITALIA SPA [IT], et al) [X] 1-56 * compounds 2775,2785, 2795, 2805 * * page 1, lines 13-17 * * claims 1-10,22 *;
 [X]WO2005075435  (VERTEX PHARMA [US], et al) [X] 1-120 * page 1, paragraph 1 * * examples 45-49,109,189,245,286 * * claims 1-137 *;
 [PX]WO2007117715  (VERTEX PHARMA [US], et al) [PX] 1-120* the whole document *
by applicantWO2005063746
 WO2005075435
 WO2007117715
    - HWANG, T. C. ET AL., J. GEN. PHYSIOL., (1998), vol. 111, no. 3, pages 477 - 90
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.